The sulfonic acid polymers PAMPS [Poly(2-acrylamido-2-methyl-1-propanesuifonie acid)] and related analogues are highly potent inhibitors of angiogenesis

Oncology Research

Volumn 9, Issue 4, 1997, Pages 173-181

  Liekens, Sandra ^a   Neyts, Johan ^a   Dégrève, Bart ^a   De Clercq, Erik ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

Angiogenesis; PAMPS; PPS, BFGF; Suramin

Indexed keywords

FIBROBLAST GROWTH FACTOR 2; GROWTH INHIBITOR; POLY(2 ACRYLAMIDO 2 METHYL 1 PROPANESULFONIC ACID); POLY(2-ACRYLAMIDO-2-METHYL-1-PROPANESULFONIC ACID); POLYMER; SULFONIC ACID DERIVATIVE;

ANGIOGENESIS; ANIMAL; ARTICLE; BIOASSAY; CELL CULTURE; CELL DIVISION; CHICK EMBRYO; CYTOLOGY; DRUG EFFECT; HUMAN; RAT; STRUCTURE ACTIVITY RELATION; VASCULAR ENDOTHELIUM;

ANIMALS; BIOLOGICAL ASSAY; CELL DIVISION; CELLS, CULTURED; CHICK EMBRYO; ENDOTHELIUM, VASCULAR; FIBROBLAST GROWTH FACTOR 2; GROWTH INHIBITORS; HUMANS; NEOVASCULARIZATION, PHYSIOLOGIC; POLYMERS; RATS; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONIC ACIDS;

EID: 0030634055     PISSN: 09650407     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Folkman, J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nature Med. 1:27-31; 1995:
2. Folkman, J. Successful treatment of an angiogenic disease. N. Engl.J. Med. 320:1211-1212; 1989.
3. Hanahan, D.; Folkman, J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86: 353-364; 1996.
4. Jenks, S. Angiogenesis research spreads to clinic (news). J. Natl. Cancer Inst. 86:742-743; 1994.
5. Folkman, J.; Klagsbrun, M. Angiogenic factors. Science 235: 442-447; 1987.
6. Takano, S.; Gately, S.; Neville, M. E.; Herblin, W. F.; Gross, J. L.; Engelhard, H.; Perricone, M.; Eidsvoog, K.; Brem, S. Suramin, an anticancer and angiosuppfessive agent, inhibits endothelial cell binding of basic fibroblast growth factor, mi-gration, proliferation, and induction of urokinase-type plasminogen activator. Cancer Res. 54:2654-2660; 1994.
7. Zugmaier, G.; Lippman, M. E.; Wellstein, A. Inhibition by pentosan polysulphate (PPS) of heparin-binding growth factors released from tumor cells and blockage by PPS of tumor growth in animals. J. Natl. Cancer Inst. 84:1716-1724; 1992.
8. Marutsuka, K.; Hasui, Y.; Asada, Y.; Naito, S.; Osada, Y.; Sumiyoshi, A. Effects of suramin on metastatic ability, proliferation, and production of urokinase-type plasminogen activator and plasminogen activator inhibitor type 2 in human renal cell carcinoma cell line SN12C-PM6. Clin. Exp. Metastasis 13:116-122; 1995.
9. Eisenberger, M. A.; Reyno, L. M.; Jodrell, D. I.; Sinibaldi, V. J.; Tkaczuk, K. H.; Sridhara, R.; Zuhowski, E. G.; Lowitt, M. H.; Jacobs, S. C.; Egorin, M. J. Suramin, an active drug for prostate cancer: Interim observations in a Phase I trial. J. Natl. Cancer Inst. 85:611-621; 1993.
10. Kehinde, E. O.; Terry, T. R.; Horsburgh, T.; Mistry, N.; Sandhu, D. P.; Bell, P. R. UK studies on suramin therapy in hormone resistant prostate cancer. Cancer Surv. 23:217-229; 1995.
11. Ciomei, M.; Pastori, W.; Mariana, M.; Sola, F.; Grandi, M.; Mongelli, N. New sulfonated distamycin A derivatives with bFGF complexing activity. Biochem. Pharmacol. 47:295-302; 1994.
12. Mariani, M.; Paio, A.; Ciomei, M.; Pastori, W.; Franzetti, C.; Melegaro, G.; Grandi, M.; Mongelli, N. In vitro activity of novel sulphonic derivatives of distamycin A. EXS 61:455458; 1992.
13. Sola, F.; Biasoli, G.; Pesenti, E.; Farao, M.; Delia Torre, P.; Mongelli, N.; Grandi, M. In vivo activity of novel sulphonic derivatives of distamycin A. EXS 61:459-462; 1992.
14. Sola, F.; Farao, M.; Ciomei, M.; Pastori, A.; Mongelli, N.; Grandi, M. FCE 27266, a sulfonic distamycin derivative, inhibits experimental and spontaneous lung and liver metastasis. Invasion Metastasis 15:222-231; 1995.
15. Mohan, P.; Schols, D.; Baba, M.; De Clercq, E. Sulphonic acid polymers as a new class of human immunodeficiency virus inhibitors. Antiviral Res. 18:139-150; 1992.
16. Ikeda, S.; Neyts, J.; Verma, S.; Wickramasinghe, A.; Mohan, P.; De Clercq, E. In vitro and in vivo inhibition of ortho- and paramyxovirus infections by a new class of sulphonic acid polymers interacting with virus-cell binding and/or fusion. Antimicrob. Agents Chemother. 38:256-259; 1994.
17. Jaffe, E. A.; Nachman, R. L.; Becker, C. G.; Minick, C. R. Culture of human endothelial cells derived from umbilical veins. J. Clin. Invest. 52:2745-2756; 1973.
18. Maragoudakis, M. E.; Panoutsakopoulou, M.; Sarmonika, M. Rate of basement membrane biosynthesis as an index to angiogenesis. Tissue Cell 20:531-539; 1988.
19. Harris-Hooker, S. A.; Gajdusek, C. M.; Wight, T. N.; Schwartz, S. M. Neovascular response induced by cultured aortic endothelial cells. J. Cell. Physiol. 114:302-310; 1983.
20. Nicosia, R. F.; Ottinetti, A. Modulation of microvascular growth and morphogenesis by reconstituted basement membrane gel in three-dimensional cultures of rat aorta: A comparative study of angiogenesis in matrigel, collagen, fibrin and plasma clot. In Vitro Cell. Dev. Biol. 26:119-128; 1990.
21. Danesi, R.; Del Bianchi, S.; Soldani, P.; Campagni, A.; La Rocca, R. V.; Myers, C. E.; Paparelli, A.; Del Tacca, M. Suramin inhibits bFGF-induced endothelial cell proliferation and angiogenesis in the chick choioallantoic membrane. Br. J. Cancer 68:932-938; 1993.
22. Kusaka, M.; Sudo, K.; Fujita, T; Marui, S.; Itoh, F.; Ingber, D.; Folkman, J. Potent anti-angiogenic action of AGM-1470: Comparison to the fumagillin parent. Biochem. Biophys. Res. Commun. 174:1070-1076; 1991.
23. Middaugh, C. R.; Mach, H.; Burke, C. J.; Volkin, D. B.; Dabora, J. M.; Tsai, P. K.; Bruner, M. W.; Ryan, J. A.; Marfia, K. E. Nature of the interaction of growth factors with suramin. Biochemistry 31:9016-9024; 1992.
24. Olander, J. V.; Connolly, D. T.; DeLarco, J. E. Specific binding of vascular permeability factor to endothelial cells. Biochem. Biophys. Res. Commun. 175:68-76; 1991.
25. Aiello, L. P.; Avery, R. L.; Arrigg, P. G.; Keyt, B. A.; Jampel, H. D.; Shah, S. T.; Pasquale, L. R.; Thieme. H.; Iwamoto, M. A.; Park, J. E. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N. Engl. J. Med. 331:1480-1487; 1995.
26. Ensoli, B.; Gendelman, R.; Markham, P.; Fiorelli, V.; Colombini, S.; Raffeld, M.; Cafaro, A.; Chang, H.-K.; Brady, J. N.; Gallo, R. C. Synergy between basic fibroblast growth factor and HIV-1 Tat protein in induction of Kaposis sarcoma. Nature 371:674-680; 1994.
27. Ensoli, B.; Markham, P.; Kao, V.; Barillari, G.; Fiorelli, V.; Gendelman, R.; Raffeld, M.; Zon, G.; Gallo, R. C. Block of AIDS-Kaposis sarcoma (KS) cell growth, angiogenesis, and lesion formation in nude mice by antisense oligonucleotide targeting basic fibroblast growth factor. J. Clin. Invest. 94: 1736-1746; 1994.
28. Myers, C.; Cooper, M.; Stein, C.; LaRocca, R.; Walther, M. M.; Weiss, G.; Choyke, P.; Dawson, N.; Steinberg, S.; Uhrich, M. M.; Cassidy, J.; Kohler, D. R.; Trepel, J.; Linehan, W. M. Suramin: A novel growth factor antagonist with activity in hormone-refractory metastatic prostate cancer. J. Clin. Oncol. 10:881-889; 1992.